0001213900-23-025902.txt : 20230403 0001213900-23-025902.hdr.sgml : 20230403 20230403092121 ACCESSION NUMBER: 0001213900-23-025902 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230329 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230403 DATE AS OF CHANGE: 20230403 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Dominari Holdings Inc. CENTRAL INDEX KEY: 0000012239 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 520849320 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-05576 FILM NUMBER: 23790918 BUSINESS ADDRESS: STREET 1: ONE ROCKEFELLER PLAZA, 11TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10020 BUSINESS PHONE: 347-321-7646 MAIL ADDRESS: STREET 1: ONE ROCKEFELLER PLAZA, 11TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10020 FORMER COMPANY: FORMER CONFORMED NAME: AIkido Pharma Inc. DATE OF NAME CHANGE: 20210111 FORMER COMPANY: FORMER CONFORMED NAME: Aikido Pharma Inc. DATE OF NAME CHANGE: 20200317 FORMER COMPANY: FORMER CONFORMED NAME: SPHERIX INC DATE OF NAME CHANGE: 20010815 8-K 1 ea176317-8k_dominari.htm CURRENT REPORT
0000012239 false 0000012239 2023-03-29 2023-03-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or Section 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 29, 2023

 

Dominari Holdings Inc.

(Exact name of registrant as specified in its charter)

         
Delaware   000-05576   52-0849320

(State or other jurisdiction

of incorporation)

  (Commission File Number)  

(IRS Employer

Identification No.)

 

One Rockefeller Plaza11th Floor

New YorkNY 10020

(703992-9325

(Address, including Zip Code and Telephone Number, including

Area Code, of Principal Executive Offices)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 par value   DOMH   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

  

Effective as of April 3, 2023, George Way, 56, was appointed as the Chief Financial Officer of Dominari Holdings Inc. (the “Company”). In his most recent role, Mr. Way served as Director of Finance and Accounting at Steward Partners from May 2017 to March 2023. He received his Bachelor of Business Administration from Pace University and is a Certified Public Accountant in the State of New York. He has no family relationship with any of the executive officers or directors of the Company. There are no arrangements or understandings between Mr. Way and any other person pursuant to which he was appointed as an officer of the Company.

 

In accordance with the terms of Mr. Way’s Employment Agreement with the Company, dated as of March 29, 2023 (the “Employment Agreement”), he will serve as the Company’s Chief Financial Officer for an initial term of three (3) years. Mr. Way’s base salary is $350,000 per year, subject to regular annual review, payable in accordance with the standard payroll practices of the Company, and subject to all withholdings and deductions, as required by law. The Employment Agreement also provides for a grant of restricted stock to Mr. Way in an amount equal to 2.0% of the Company’s outstanding common stock on March 29, 2023, on or before April 18, 2023. This restricted stock award has not yet been granted. Upon grant, the award will vest in equal amounts over a period of three (3) years on the anniversary of the grant date, subject to certain rights of acceleration upon a change of control and as otherwise provided in the Employment Agreement. Mr. Way is also entitled to an annual bonus, as determined by the Company’s Compensation Committee, based on certain performance criteria, provided that such annual bonus will not be less than $50,000 for fiscal year 2023. Annual bonuses and all stock-based compensation are subject to certain clawback rights as provided in the Employment Agreement.

 

 Mr. Way is also entitled to the payment or reimbursement of all reasonable out-of-pocket expenses. Pursuant to the terms of the Employment Agreement, Mr. Way is also provided with all health and other benefits provided by the Company to its senior executive employees.

 

The Employment Agreement also provides for customary events of termination of employment and provides that in the event of termination as a result of Mr. Way’s death or disability, Mr. Way is entitled to severance consisting of (i) six (6) months of his then current base salary; (ii) payment on a pro-rated basis of an annual bonus for the year of termination (which shall be deemed to equal 50% of his then current base salary); (iii) any unpaid annual bonus earned for the prior year; and (iv) any other payments earned in connection with any bonus plan to which Mr. Way was a participant as of the date of death or disability. In the event of termination of Mr. Way’s employment (i) as a result of the non-renewal of the Employment Agreement by the Company at the end of the then current term, (ii) by Mr. Way, for Good Reason (as such term is defined in the Employment Agreement), or (iii) by the Company, without Cause (as such term is defined in the Employment Agreement), then Mr. Way is entitled to the same severance as provided above. Additionally, if termination is by Mr. Way, for Good Reason, or by the Company, without Cause, or upon a change in control, then all equity grants held by Mr. Way will immediately vest.

 

The above description of the Employment Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Employment Agreement filed herewith as Exhibit 10.1.

 

Item 9.01. Financial Statements and Exhibits.

 

Set forth below is a list of Exhibits included as part of this Current Report.

 

Exhibit No.   Description
10.1*   Employment Agreement, made and entered into as of March 29, 2023, by and between Dominari Holdings Inc. and George M. Way
99.1*   Press Release Announcing George Way as the Chief Financial Officer of Dominari Holdings Inc.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: April 3, 2023 DOMINARI HOLDINGS INC.
     
  By:

/s/ Anthony Hayes

  Name:  Anthony Hayes
  Title: Chief Executive Officer

 

 

2

 

EX-10.1 2 ea176317ex10-1_dominari.htm EMPLOYMENT AGREEMENT, MADE AND ENTERED INTO AS OF MARCH 29, 2023, BY AND BETWEEN DOMINARI HOLDINGS INC. AND GEORGE M. WAY

eXHIBIT 10.1

 

EMPLOYMENT AGREEMENT

 

THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into on March 29, 2023, by and between Dominari Holdings, Inc., a Delaware corporation with offices at 725 5th Avenue, New York, NY 10022 (the “Corporation”), and George M. Way, an individual residing 156 Firethorne Trail, Basking Ridge, NJ 07920-3176 (the “Executive”), under the following circumstances:

 

RECITALS:

 

A. The Corporation desires to secure the services of the Executive upon the terms and conditions hereinafter set forth;

 

B. The Executive desires to render services to the Corporation upon the terms and conditions hereinafter set forth; and

 

C. The Corporation and the Executive desire for this Agreement to constitute and embody their full and complete understanding and agreement with respect to the Executive’s employment by the Corporation and supersede, as of the date hereof, all prior understandings and agreements, whether oral or written, between them with respect to such employment.

 

NOW, THEREFORE, the parties mutually agree as follows:

 

1. Employment. The Corporation hereby employs the Executive, and the Executive hereby accepts employment as an executive of the Corporation, subject to the terms and conditions set forth in this Agreement.

 

2. Duties and Place of Employment. The Executive shall serve as the Chief Financial Officer of the Corporation, with such duties, responsibilities, and authority as are commensurate and consistent with his position, and such other duties, responsibilities and authority as may be, from time to time, reasonably assigned to him by the Chief Executive Officer of the Corporation (the “CEO”) or the Board of Directors of the Corporation (the “Board”). The Executive shall report directly to the CEO and the Board. During the Term (as defined in Section 3), the Executive shall devote his full business time and efforts to the performance of his duties hereunder unless otherwise authorized by the CEO or the Board. Notwithstanding the foregoing, the expenditure of reasonable amounts of time by the Executive for the making of passive personal investments (including, without limitations equity interests in Steward Partners Holdings, LLC), the conduct of private business affairs, and charitable and professional activities shall be allowed, provided such activities do not materially interfere with the services required to be rendered to the Corporation hereunder and do not violate the confidentiality provisions set forth in Section 8 below. The Executive shall perform his services for the Corporation at the Corporation’s offices at 725 5th Avenue, New York, NY 10022, or such other location as mutually agreed to by the parties.

 

3. Term of Employment. The term of this Agreement shall commence on April 3, 2023 (the “Effective Date”) and shall be for three (3) years (the “Initial Term”) and automatically be extended for additional terms of one (1) year each (each a “Renewal Term”) unless either party gives prior written notice of non-renewal to the other party no later than three (3) months prior to the expiration of the Initial Term (“Non-Renewal Notice”), or the then current Renewal Term, as the case may be. For purposes of this Agreement, the Initial Term and any Renewal Term, as the same may be earlier terminated in accordance with Section 5, are hereinafter collectively referred to as the “Term.”

 

 

 

 

4. Compensation of Executive.

 

(a) The Corporation shall pay the Executive as compensation for his services hereunder, in equal installments during the Term in accordance with the Corporation’s payroll practices the sum of $350,000 per annum (the “Base Salary”), less such deductions as shall be required to be withheld by applicable law and regulations. The Board, or the Compensation Committee of the Board (the “Compensation Committee”), shall review the Base Salary annually and shall have the right but not the obligation to increase the Base Salary as it deems appropriate in its discretion.

 

(b) This section intentionally left blank.

 

(c) In addition to the Base Salary, the Executive shall be entitled to receive an annual bonus from the Corporation (“Annual Bonus”) in an amount determined by the Board in its sole discretion, with a target amount equal to 100% of the Base Salary for the applicable year if the performance target established by the Board is achieved; provided, that for 2023, the Executive shall be paid an Annual Bonus of no less than $50,000. Annual Bonuses shall be paid by the Corporation to the Executive after the applicable year end, but not later than March 15 following such year end, in cash or in shares of the Corporation’s common stock at the Corporation’s discretion, it being understood that the Board’s determinations concerning attainment of any financial targets associated with any Annual Bonus calculation shall not be made until following the completion of the Corporation’s annual audit and public announcement of such results and shall be paid promptly following the Corporation’s announcement of earnings, but in no event later than December 31 of the year following the year for which the Annual Bonus is being paid (and if the Executive was employed on April 15th of the year following the year to which such Annual Bonus relates, then the Executive shall be entitled to the Annual Bonus for such year, even if he is not employed by the Corporation on the date on which such Annual Bonus is paid).

 

(d) The Board shall approve a restricted stock grant to the Executive (the “Restricted Stock Grant”) under and subject to the terms of the Corporation’s 2022 Equity Incentive Plan with respect to shares representing at least 2% of the Corporation’s outstanding common stock as of the Effective Date. The Restricted Stock Grant shall be completed within twenty (20) days of the Effective Date (the “Grant Date”) and shall vest on a pro rata basis on each of the three (3) annual anniversaries of the Grant Date. Notwithstanding the foregoing, the Restricted Stock Grant shall immediately vest in full if during the Term there is (i) a Change in Control Transaction, (ii) a termination of the Executive’s services hereunder by the Corporation other than for “Cause” (as hereinafter defined), (iii) a termination by the Executive for Good Reason (as hereinafter defined), or (iv) as a result of the Executive’s death or Total Disability (as hereinafter defined).

 

(e) If the Corporation engages in an unbrokered (e.g., “friends and family”) offering of its securities, the Executive shall be entitled to participate in such offering in such manner as the Compensation Committee, in its discretion, shall decide.

 

2

 

 

(f) The Corporation shall pay or reimburse the Executive for all reasonable out-of-pocket expenses actually incurred or paid by the Executive in the course of his employment, consistent with the Corporation’s written policy for reimbursement of expenses applicable to similarly situated employees of the Corporation. In addition, the Corporation will (i) reimburse the Executive for his attorney’s fees incurred in connection with the preparation and negotiation of this Agreement up to a maximum of $5,000 and (ii) provide the Executive a cell phone for his dedicated business usage during the Term.

 

(g) The Executive shall be entitled to participate in such pension, profit sharing, group insurance, hospitalization, and group health and benefit plans and all other benefits and plans, including perquisites, if any, as the Corporation provides to its employees generally, including group family health insurance coverage, which shall be paid by the Corporation (the “Benefit Plans”).

 

(h) The Corporation shall maintain directors’ and officers’ insurance during the Term and for a period of at least six (6) years thereafter.

 

5. Termination.

 

(a) This Agreement and the Term shall terminate upon the first to occur of the following events:

 

(i) the Executive’s death:

 

(ii) the Executive’s Total Disability;

 

(iii) the expiration of the Initial Term of this Agreement or any Renewal Term thereof, if either party has provided a timely Non-Renewal Notice in accordance with Section 3;

 

(iv) at the Executive’s option, upon ninety (90) days prior written notice to the Corporation, without Good Reason;

 

(v) at the Executive’s option, for Good Reason, as defined in Section 5(e)

 

(vi) at the Corporation’s option, for Cause, as defined in Section 5(e); and

 

(vii) at the Corporation’s option, upon ninety (90) days prior written notice to the Executive, without Cause.

 

(b) For purposes of this Agreement, the Executive shall be deemed to be suffering from a “Total Disability” if the Executive has failed to perform his regular and customary duties to the Corporation for a period of 180 days out of any 360-day period and if before the Executive has become “Rehabilitated” (as herein defined) a majority of the members of the Board, exclusive of the Executive, determine that the Executive is mentally or physically incapable or unable to continue to perform such regular and customary duties of employment. As used herein, the term “Rehabilitated” shall mean such time as the Executive is willing, able, and commences to devote his time and energies to the affairs of the Corporation to the extent and in the manner that he did so prior to his Total Disability.

 

3

 

 

(c) For purposes of this Agreement, the term “Change in Control Transaction” means the sale of the Corporation to an un-affiliated person or entity or group of un-affiliated persons or entities pursuant to which such party or parties acquire (i) shares of capital stock of the Corporation representing at least fifty percent (50%) of outstanding capital stock or sufficient to elect a majority of the Board or of the board of directors of the Corporation (whether by merger, consolidation, sale, or transfer of shares (other than a merger where the Corporation is the surviving corporation and the shareholders and directors of the Corporation prior to the merger constitute a majority of the shareholders and directors, respectively, of the surviving corporation (or its parent)) or (ii) all or substantially all of the Corporation’s assets determined on a consolidated basis.

 

(d) For purposes of this Agreement, the term “Cause” shall mean (i) any material breach of this Agreement by Executive or material, gross, and willful misconduct on the part of the Executive in connection with his employment duties hereunder, in all cases that is not cured within fourteen (14) days after receipt of notice thereof (to the extent such breach is capable of being cured), (ii) the Executive’’s conviction of or entering of a guilty plea or a plea of no contest with respect to a felony or any crime involving fraud, larceny, or embezzlement resulting in material harm to the Corporation by the Executive, or (iii) the failure by the Executive to take and pass the FINRA Series 24 and 27 examinations within 365 days of the Effective Date and furnish acceptable proof of his having obtained such licenses.

 

(e) For purposes of this Agreement, the term “Good Reason” shall mean that the Executive has resigned due to: (i) a material diminution of duties inconsistent with Executive’s title, authority, duties, and responsibilities (including, without limitation, a change in the chain of reporting) prior to such diminution; or (ii) any material violation by the Corporation of its obligations (including, without limitation, its compensation obligations) under this Agreement; provided that the Executive has given written notice to the Corporation within ninety (90) days of Executive’s knowledge of the initial occurrence of such event, and the Corporation has failed to cure such acts within thirty (30) days of receipt of such notice, if curable, and the Executive must then terminate his employment within thirty (30) days following the expiration of such cure period for the termination to be on account of Good Reason.

 

6. Effects of Termination.

 

Upon termination of employment for any reason, whether by the Executive or the Corporation, the Executive shall be paid (i) accrued but unpaid Base Salary and vacation pay through the date of termination; (ii) if the date of such termination is on or after April 15th, the full Annual Bonus earned but not yet paid for the year immediately preceding the year of termination; (iii) any other benefits vested or accrued to him under any Benefit Plans outstanding at the date of termination; (iv) the reimbursement of documented, unreimbursed expenses incurred on or prior to such termination date; and (v) all statutory entitlements as may be required to be paid or provided under applicable law, all paid as promptly as practicable and in accordance with applicable law (collectively, “Base Benefits”), and the Executive shall have any conversion rights available under the Benefit Plans and as otherwise provided by law, including the Consolidated Omnibus Budget Reconciliation Act and any similar state law or regulation (“COBRA”).

 

4

 

 

The following provisions apply to specified termination events. Any Annual Bonus (including any pro-rated Annual Bonus) payable pursuant to the following provisions shall be paid at the same time that it would have been paid if the Executive’s employment had not terminated.

 

(a) Upon termination of the Executive’s employment pursuant to Section 5(a)(i) or (ii), in addition to the Base Benefits, which will not be conditioned on a Release (as defined below), upon the execution by the Executive (or his estate or beneficiaries, as applicable) of a general release of claims in such form acceptable to the Corporation (a “Release”), the Executive or his estate or beneficiaries, as applicable, shall be entitled to the following severance benefits: (i) six (6) months of Base Salary at the then current rate, payable in a lump sum, less withholding of applicable taxes, within thirty (30) days of the date of termination; (ii) if the Executive elects continuation coverage for group health coverage pursuant to COBRA, then for a period of six (6) months following the Executive’s termination he will be obligated to pay only the portion of the full COBRA cost of the coverage equal to an active employee’s share of premiums (if any) for coverage for the respective plan year and, to the extent required by any applicable nondiscrimination rules, the Company’s share of such premiums (the “Employer-Provided COBRA Premium”) shall be treated as taxable income to the Executive; (iii) the Annual Bonus for the year of termination, which shall be deemed to equal (x) 50% of the Base Salary multiplied by (y) a fraction, the numerator of which is equal to the number of calendar days from the beginning of such year through the termination date, and the denominator of which is equal to 365, payable in a lump sum, less withholding of applicable taxes, within thirty (30) days of the date of termination; (iv) if the date of such termination is prior to April 15th, any Annual Bonus earned but not yet paid for the year immediately preceding the year of termination, payable in a lump sum, less withholding of applicable taxes, within thirty (30) days of the date of termination; and (v) any other payments earned in connection with any bonus plan to which the Executive was a participant as of the date of death or Total Disability. This Section 6(a) shall not terminate or otherwise interfere with any right to disability payments.

 

(b) Upon termination of the Executive’s employment pursuant to Section 5(a)(iii), where the Corporation tenders a Non-Renewal Notice to the Executive, then the Executive shall be entitled to the same severance benefits as if the Executive’’’s employment was terminated without Cause pursuant to Section 5(a)(vii); provided, however, if such Non-Renewal Notice was triggered due to the Corporation’s statement that the Executive’s employment was terminated for Cause pursuant to Section 5(a)(vi), then payment of the severance benefits under this sentence will be contingent upon a determination as to whether termination was properly for Cause.

 

(c) Upon termination of the Executive’s employment pursuant to Section 5(a)(v) or 5(a)(vii), in addition to the Base Benefits, which will not be conditioned on a Release, upon the execution by the Executive of a Release, the Executive shall be entitled to the following severance benefits: (i) six (6) months Base Salary at the then current rate, to be paid in a single lump sum payment not later than thirty (30) days following such termination, less withholding of all applicable taxes; (ii) if the Executive elects continuation coverage for group health coverage pursuant to COBRA, then for a period of six (6) months following the Executive’s termination he will be obligated to pay only the portion of the full COBRA cost of the coverage equal to an active employee’s share of premiums (if any) for coverage for the respective plan year and, to the extent required by any applicable nondiscrimination rules, the Employer-Provided COBRA Premium shall be treated as taxable income to the Executive; (iii) the Annual Bonus for the year of termination, which shall be deemed to equal (x) 50% of the Base Salary multiplied by (y) a fraction, the numerator of which is equal to the number of calendar days from the beginning of such year through the termination date, and the denominator of which is equal to 365, payable in a lump sum, less withholding of applicable taxes, within thirty (30) days of the date of termination; (iv) if the date of such termination is prior to April 15th, any Annual Bonus earned but not yet paid for the year immediately preceding the year of termination, payable in a lump sum, less withholding of applicable taxes, within thirty (30) days of the date of termination; and (v) any other payments earned in connection with any bonus plan to which the Executive was a participant as of the date of the Executive’s termination of employment. In addition, any equity grants to Executive shall be immediately vested upon termination of Executive’s employment pursuant to Section 5(a)(v) or 5(a)(vii).

 

5

 

 

(d) Upon termination of the Executive’s employment pursuant to Section 5(a)(iii), where the Executive tenders a Non-Renewal Notice to the Corporation, or Section 5(a)(iv), in addition to the Base Benefits, which will not be conditioned on a Release, upon the execution by the Executive of a Release, the Executive shall be entitled to COBRA benefits as follows: if the Executive elects continuation coverage for group health coverage pursuant to COBRA, then, for a period of one (1) month following the Executive’s termination, he will be obligated to pay only the portion of the full COBRA cost of the coverage equal to an active employee’s share of premiums (if any) for coverage for one month of the respective plan year and, to the extent required by any applicable nondiscrimination rules, the Employer-Provided COBRA Premium shall be treated as taxable income to the Executive.

 

(e) Upon termination of the Executive’s employment pursuant to Section 5(a)(vi), the Executive shall only be entitled to the Base Benefits.

 

(f) Any payments required to be made hereunder by the Corporation to the Executive shall continue to the Executive’s beneficiaries in the event of his death until paid in full.

 

7. Vacations. The Executive shall be entitled to three (3) weeks of paid vacation per year. The Executive shall take his vacation at such time or times as the Executive and the CEO shall determine is mutually convenient. Any vacation not taken in one (1) year shall accrue, up to a maximum of six (6) weeks of vacation and shall carry over to the subsequent year.

 

8. Disclosure of Confidential Information. The Executive recognizes, acknowledges and agrees that he will have access to secret and confidential information regarding the Corporation and-its affiliates, including but not limited to, its products, formulae, patents, sources of supply, customer dealings, data, know-how, and business plans, provided such information is not in or does not hereafter become part of the public domain, or become known to others through no fault of the Executive. The Executive acknowledges that such information is of great value to the Corporation, is the sole property of the Corporation, and has been and will be acquired by him in confidence. In consideration of the obligations undertaken by the Corporation herein, the Executive will not, at any time, during or after the Term of his employment hereunder, reveal, divulge, or make known to any person any information acquired by the Executive during the course of his employment, which is treated as confidential by the Corporation, and not otherwise in the public domain. Notwithstanding the foregoing, nothing in this Section 8 shall prohibit the Executive from providing information or testimony if ordered by a court of competent jurisdiction, governmental authority or stock exchange to disclose such information, provided that in such circumstance, if legally permissible and practicable, the Executive shall provide prompt written notice of such order to the Corporation to enable the Corporation to seek a protective order prior to making such disclosure of such information. The provisions of this Section 8 shall survive the termination of the Executive’s employment hereunder. All references to the Corporation in Sections 8 and 9 hereof shall include affiliates of the Corporation.

 

6

 

 

9. Clawback Rights. All Annual Bonuses, and any and all stock-based compensation (such as options, restricted stock units and other equity awards) (collectively, the “Clawback Benefits”) shall be subject to “Clawback Rights” as follows. During the period that the Executive is employed by the Corporation and upon the termination of the Executive’s employment and for a period of three (3) years thereafter, if there is a restatement of any financial results from which any Clawback Benefits to Executive shall have been determined, the Executive agrees to repay any amounts that were determined by reference to any financial results of the Corporation that were later restated (as defined below), to the extent the Clawback Benefits paid exceed the Clawback Benefits that would have been paid, based on the restatement of the Corporation’s financial information. All Clawback Benefits resulting from such restated financial results shall be retroactively adjusted by the Compensation Committee to take into account the restated results, and any excess portion of the Clawback Benefits resulting from such restated results shall be immediately surrendered to the Corporation and if not so surrendered within ninety (90) days of the revised calculation being provided to the Executive by the Compensation Committee following a publicly announced restatement, the Corporation shall have the right to take any and all actions to effectuate such adjustment. The calculation of the revised Clawback Benefits shall be determined by the Compensation Committee in good faith and in accordance with any applicable laws, rules, and regulations. All determinations by the Compensation Committee with respect to the Clawback Rights shall be final and binding on the Corporation and the Executive. The Clawback Rights shall terminate following a Change of Control Transaction, subject to applicable laws, rules, and regulations. For purposes of this Section 9, a restatement of financial results that requires a repayment of all or a portion of the Clawback Benefits shall mean a restatement resulting from material noncompliance of the Corporation with any financial reporting requirement under the federal securities laws and shall not include a restatement of financial results resulting from subsequent changes in accounting pronouncements or requirements that were not in effect on the date the financial statements were originally prepared (“Restatements”). The parties acknowledge that it is their intention that the foregoing Clawback Rights as relates to Restatements conform in all respects to the provisions of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the “Dodd-Frank Act”) and requires recovery of all “incentive-based” compensation, pursuant to the provisions of the Dodd-Frank Act and any and all rules and regulations promulgated thereunder from time to time. Accordingly, the terms and conditions of this Agreement shall be deemed automatically amended from time to time to the extent required to assure compliance with the Dodd-Frank Act or any applicable rules or regulations enacted thereunder that may be adopted by the Securities and Exchange Commission or any stock exchange on which the securities of the Company are listed.

 

10. Section 409A.

 

(a) The provisions of this Agreement are intended to comply with or be exempt from Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”) and any final regulations and guidance promulgated thereunder (“Section 409A”) and shall be construed in a manner consistent with the requirements for avoiding taxes, interest or penalties under Section 409A. The Corporation and the Executive agree to work together in good faith to consider amendments to this Agreement and to take such reasonable actions that are necessary, appropriate, or desirable to avoid imposition of any additional tax, penalties or income recognition prior to actual payment to the Executive under Section 409A; provided however, that the Corporation has no obligation to indemnify the Executive or hold the Executive harmless from any adverse tax consequences related to any failure to comply with Section 409A.

 

(b) To the extent that the Executive will be reimbursed for costs and expenses or in-kind benefits, except as otherwise permitted by Section 409A, (i) the right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit, (ii) the amount of expenses eligible for reimbursement, or in-kind benefits, provided during any taxable year shall not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other taxable year; provided, that the foregoing clause (ii) shall not be violated with regard to expenses reimbursed under any arrangement covered by Section 105(b) of the Code solely because such expenses are subject to a limit related to the period the arrangement is in effect, and (iii) such payments shall be made on or before the last day of the taxable year following the taxable year in which Executive incurred the expense.

 

7

 

 

(c) A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits upon or following a termination of employment unless such termination constitutes a “Separation from Service” within the meaning of Section 409A and, for purposes of any such provision of this Agreement references to a “termination,” “termination of employment,” or like terms shall mean Separation from Service.

 

(d) Each payment that is made within the terms of the “short-term deferral” rule set forth in Treasury Regulation Section 1.409A-1(b)(4) is intended to meet the “short-term deferral” rule. Each other payment is intended to be a payment upon an involuntary separation from service and payable pursuant to Treasury Regulation Section 1.409A-1(b)(9)(iii), et seq., to the maximum extent permitted by that regulation, with any amount that is not exempt from Section 409A being subject to Section 409A.

 

(e) Notwithstanding anything to the contrary in this Agreement, if the Executive is a “specified employee” within the meaning of Section 409A at the time of Executive’s termination, then only that portion of the severance and benefits payable to the Executive pursuant to this Agreement, if any, and any other severance payments or separation benefits that may be considered deferred compensation under Section 409A (together, the “Deferred Compensation Separation Benefits”), which (when considered together) do not exceed the Section 409A Limit (as defined herein) may be made within the first six (6) months following the Executive’s termination of employment in accordance with the payment schedule applicable to each payment or benefit. Any portion of the Deferred Compensation Separation Benefits in excess of the Section 409A Limit otherwise due to Executive on or within the six (6) month period following the Executive’s termination will accrue during such six (6) month period and will become payable in one lump sum cash payment on the date six (6) months and one (1) day following the date of the Executive’s termination of employment. All subsequent Deferred Compensation Separation Benefits, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit. Notwithstanding anything herein to the contrary, if the Executive dies following termination but prior to the six (6) month anniversary of the Executive’s termination date, then any payments delayed in accordance with this paragraph will be payable in a lump sum as soon as administratively practicable after the date of the Executive’s death and all other Deferred Compensation Separation Benefits will be payable in accordance with the payment schedule applicable to each payment or benefit.

 

(f) Each payment and benefit payable under this Agreement, including any payment or benefit that is required to be aggregated with such payment and benefit under Section 409A, is hereby designated as a separate payment, and will not collectively be treated as a single payment, as provided in Treasury Regulation Section 1.409A-2(b)(2)(iii).

 

(g) For purposes of this Agreement, “Section 409A Limit” will mean a sum equal (x) to the amounts payable prior to March 15 following the year in which Executive’s employment termination date occurs, plus (y) the lesser of two (2) times: (i) Executive’s annualized compensation based upon the annual rate of pay paid to Executive during the Corporation’s taxable year preceding the Corporation’s taxable year which includes Executive’s date of termination of employment as determined under Treasury Regulation 1.409A-1(b)(9)(iii)(A)(1); or (ii) the maximum amount that may be taken into account under a tax-qualified plan pursuant to Section 401(a)(17) of the Code for the year in which Executive’s Separation from Service occurs.

 

8

 

 

11. Miscellaneous.

 

(a) The Executive acknowledges that the services to be rendered by him under this Agreement are of a special, unique, and extraordinary character and that it would be difficult or impossible to replace such services. Accordingly, the Executive agrees that any breach or threatened breach by him of Section 8 or 9 of this Agreement shall entitle the Corporation, in addition to all other legal remedies available to it, to apply to any court of competent jurisdiction to seek to enjoin such breach or threatened breach. The parties understand and intend that each restriction agreed to by the Executive hereinabove shall be construed as separable and divisible from every other restriction, that the unenforceability of any restriction shall not limit the enforceability, in whole or in part, of any other restriction, and that one or more or all of such restrictions may be enforced in whole or in part as the circumstances warrant. In the event that any restriction in this Agreement is more restrictive than permitted by law in the jurisdiction in which the Corporation seeks enforcement thereof, such restriction shall be limited to the minimum extent permitted by law. The remedy of injunctive relief herein set forth shall be in addition to, and not in lieu of, any other rights or remedies that the Corporation may have at law or in equity.

 

(b) Neither the Executive nor the Corporation may assign or delegate any of their rights or duties under this Agreement without the express written consent of the other; provided however, that the Corporation shall have the right to delegate its obligation of payment of all sums due to the Executive hereunder, provided that such delegation shall not relieve the Corporation of any of its obligations hereunder.

 

(c) This Agreement constitutes and embodies the full and complete understanding and agreement of the parties with respect to the Executive’s employment by the Corporation, supersedes, as of the date hereof, all prior understandings and agreements, whether oral or written, between the Executive and the Corporation with respect to such employment, and shall not be amended, modified, or changed except by an instrument in writing executed by the party to be charged. The invalidity or partial invalidity of one or more provisions of this Agreement shall not invalidate any other provision of this Agreement. No waiver by either party of any provision or condition to be performed shall be deemed a waiver of similar or dissimilar provisions or conditions at the same time or any prior or subsequent time.

 

(d) This Agreement shall inure to the benefit of, and be binding upon and enforceable against, the parties hereto and their respective successors, heirs, beneficiaries, and permitted assigns.

 

(e) The headings contained in this Agreement are for convenience of reference only and shall not affect in any way the meaning or interpretation of this Agreement.

 

(f) All notices, requests, demands, and other communications required or permitted to be given hereunder shall be in writing and shall be deemed to have been duly given when personally delivered, sent by registered or certified mail, return receipt requested, postage prepaid, or by private overnight mail service (e.g. Federal Express) to the applicable party at the address set forth above, or when sent by email to the Executive at gwayiii@gmail.com or to the CEO of the Corporation at ahayes@dominari.com, or to such other address or email as either party may hereafter give notice of in accordance with the provisions hereof. Notices shall be deemed given on the sooner of the date actually received or the third business day after sending.

 

(g) This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York without reference to principles of conflicts of laws and each of the parties hereto irrevocably consents to the jurisdiction and venue of the federal and state courts located in the State of New York.

 

(h) This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one of the same instrument, and may be delivered by electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and so delivered shall be deemed to have been duly and validly executed and delivered and be valid and effective for all purposes.

 

9

 

 

The parties hereto have executed this Agreement as of the date first written above.

 

DOMINARI HOLDINGS, INC  
     
By: /s/ Anthony Hayes  
  Anthony Hayes, Chief Executive Officer  

 

EXECUTIVE:  
   
/s/ George Way  
George Way  

 

 

 

 

 

EX-99.1 3 ea176317ex99-1_dominari.htm PRESS RELEASE ANNOUNCING GEORGE WAY AS THE CHIEF FINANCIAL OFFICER OF DOMINARI HOLDINGS INC

EXHIBIT 99.1

 

 

Dominari Holdings Appoints George Way Chief Financial Officer

 

Experienced Finance Executive to Support Growth Strategy

 

New York, April 3, 2023 – Dominari Holdings Inc. (Nasdaq: DOMH) (“Dominari” or the “Company”) today announced that George Way has been named Chief Financial Officer effective April 3, 2023. Mr. Way brings more than 30 years of experience in finance, accounting, acquisitions and investments, and has a proven track record of solving complex business challenges.

 

“George is a highly talented and accomplished finance executive with decades of experience that will be extremely valuable as we grow our financial services business,” said Anthony Hayes, CEO of Dominari. “He has a critical understanding of what it takes to drive growth and operational excellence in a finance organization. In prior roles, he has been instrumental in establishing and effectively managing robust financial operations and taking firms from start up to a scalable enterprise.”

 

Most recently, Mr. Way served as Director of Finance and Accounting of Steward Partners, a wealth advisory and asset management firm. While in this role, Steward Partners expanded significantly. Prior to that, he served as Chief Operating Officer at RidgeWorth Investments, Seix Investment Advisors where he was responsible for operations, technology and infrastructure and the consolidation of central service platforms. In this role, he successfully managed the merger of six systems into three to create a seamless front-to-back processing platform and facilitated a reduction in operating costs through process improvements and real estate negotiations. Mr. Way began his career in the Asset Management Practice at Deloitte & Touche LLP. He holds a Bachelor of Business Administration from Pace University and is a licensed Certified Public Accountant.

 

Mr. Way commented, “Creating a results-driven finance function that serves the needs of Dominari’s advisors and enhances shareholder value is my primary objective.  This mindset, along with placing clients first by attracting only the best in the financial advisor space, will be the key to executing Anthony’s vision and creating an industry leading wealth advisory firm.” 

 

Dominari Financial Inc. Mission Statement:

 

Dominari Financial is a dynamic, forward-thinking financial services company that seeks to create wealth for all stakeholders by capitalizing on emerging trends in the financial services sector and identifying early-stage future opportunities that are expected to generate a high rate of return for investors.

 

 

 

 

Securities Brokerage and Registered Investment Adviser Services are offered through Fieldpoint Private Securities LLC, Member FINRA, MSRB and SIPC, which will be known as Dominari Securities LLC after its name change is effective. Securities brokerage, investment adviser and other non-bank deposit investments are not FDIC insured and may lose some or all of the principal invested. You can check the background of Fieldpoint Securities and its registered investment professionals and review its SEC Form CRS on FINRA’s BrokerCheck site at https://brokercheck.finra.org. After the name change, information for Dominari Securities LLC and its registered investment professionals as well as its SEC Form CRS may also be found on FINRA’s BrokerCheck site.

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the SEC, which include but are not limited to the Risk Factors set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 relating to its business. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

 

Contact:

Investor Relations

Hayden IR

Brett Maas, Managing Partner

Phone: (646) 536-7331

Email: brett@haydenir.com

www.haydenir.com

 

 

 

 

 

GRAPHIC 4 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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bp2a-20230329.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 6 bp2a-20230329_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 bp2a-20230329_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover
Mar. 29, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 29, 2023
Entity File Number 000-05576
Entity Registrant Name Dominari Holdings Inc.
Entity Central Index Key 0000012239
Entity Tax Identification Number 52-0849320
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One One Rockefeller Plaza
Entity Address, Address Line Two 11th Floor
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10020
City Area Code 703
Local Phone Number 992-9325
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value
Trading Symbol DOMH
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 9 ea176317-8k_dominari_htm.xml IDEA: XBRL DOCUMENT 0000012239 2023-03-29 2023-03-29 iso4217:USD shares iso4217:USD shares 0000012239 false 8-K 2023-03-29 Dominari Holdings Inc. DE 000-05576 52-0849320 One Rockefeller Plaza 11th Floor New York NY 10020 703 992-9325 false false false false Common Stock, $0.0001 par value DOMH NASDAQ false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://aikidopharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea176317-8k_dominari.htm bp2a-20230329.xsd bp2a-20230329_lab.xml bp2a-20230329_pre.xml ea176317ex10-1_dominari.htm ea176317ex99-1_dominari.htm http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ea176317-8k_dominari.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "ea176317-8k_dominari.htm" ] }, "labelLink": { "local": [ "bp2a-20230329_lab.xml" ] }, "presentationLink": { "local": [ "bp2a-20230329_pre.xml" ] }, "schema": { "local": [ "bp2a-20230329.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "BP2A", "nsuri": "http://aikidopharma.com/20230329", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "ea176317-8k_dominari.htm", "contextRef": "From2023-03-29to2023-03-29", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://aikidopharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "ea176317-8k_dominari.htm", "contextRef": "From2023-03-29to2023-03-29", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001213900-23-025902-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-23-025902-xbrl.zip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